# Efficacy of Early Terlipressin Plus Albumin Therapy in Comparison to Standard Treatment for HRS-AKI in Acute-on-chronic Liver Failure.

> **NCT04416282** · NA · COMPLETED · sponsor: **Institute of Liver and Biliary Sciences, India** · enrollment: 70 (actual)

## Conditions studied

- Acute-On-Chronic Liver Failure
- Hepatorenal Syndrome
- Acute Kidney Injury

## Interventions

- **DRUG:** Terlipressin
- **BIOLOGICAL:** Albumin

## Key facts

- **NCT ID:** NCT04416282
- **Lead sponsor:** Institute of Liver and Biliary Sciences, India
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-22
- **Primary completion:** 2022-06-10
- **Final completion:** 2022-06-10
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2023-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04416282

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04416282, "Efficacy of Early Terlipressin Plus Albumin Therapy in Comparison to Standard Treatment for HRS-AKI in Acute-on-chronic Liver Failure.". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04416282. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*